OrthoSensor has raised money through Series C preferred stock financing.
Here are five things to know:
1. OrthoSensor raised $19 million in a private placement of Series C Preferred Stock.
2. Bridger Healthcare and The Tullis Growth Fund participated in the round.
3. The company plans to use proceeds to drive VERASENSE commercialization.
4. The VERASENSE technology is a disposable sensor-assisted total knee replacement instrument.
5. There is a two-year multicenter evaluation of the technology that will be presented at the 2015 American Academy of Orthopaedic Surgeons annual meeting.
"We have an exciting path forward and believe that the support of high-profile investors such as Bridger Healthcare and The Tullis Growth Fund illustrates broad potential impact of our technology in the future of orthopedics," said OrthoSensor President and CEO Ivan Delevic.